Tepapro 100mg Injection belongs to the class of medication known as Antineoplastics. It contains the active ingredient Thiotepa. It is prescribed in combination with other anti-cancer drugs before stem cell transplantation for adult patients with cancer in the lymph nodes of the central nervous system. It is used as a Preparation before stem cell transplant to reduce the risk of graft rejection. It controls the outflow within the cavity due to cancer in serous membranes. It is also indicated for treating breast, ovarian, and bladder cancer.

The common side effects that are likely to be associated with Tepapro 100mg Injection are diarrhea, rashes, bleeding, blood in urine, and cytomegalovirus infection. Inform your doctor if these side effects disturb or persist in you. 

Inform your healthcare provider if you are allergic (hypersensitive) to Tepapro 100mg Injection and its ingredients. It is contraindicated in patients using a live virus or bacterial vaccine, including the yellow fever vaccine. If you have a history of cardiac, liver, kidney, and pulmonary disease and profound myelosuppression (anemia, neutropenia, and thrombocytopenia), report to your doctor. Liver and cardiac function must be monitored regularly, and caution is advised in patients with cardiac disease and liver impairment. It is not recommended to use in pregnant and breastfeeding women. 

• Preparation for allogeneic hematopoietic stem cell transplantation in pediatric patients with class 3 beta-thalassemia
• Treatment of adenocarcinoma of breast and ovary.
• Treatment of superficial papillary cancer of the urinary bladder.

Tepapro 100mg Injection acts by damaging the genetic material (DNA and RNA) of the cancer cells. It stops the growth and multiplication of cancer by directly attacking DNA. This causes the breakage of DNA strands. This leads to the exertion of cytotoxic effect and death of tumor cells.

Inform your physician about all the prescribed medications, over-the-counter medications, nutritional and vitamin supplements, and herbal products that you take or have taken before the treatment. Certain medications tend to interact with Thioplan 15 mg Injection and can cause undesirable side effects

• Store between 2° to 8°C.
• Protect from light.
• Keep out of reach of children.
• Do not freeze

Tepapro 100mg Injection should be administered strictly under the supervision of a healthcare professional. It is given as an intravenous (IV) infusion or injection, usually in a hospital or clinical setting. The dosage and frequency depend on the patient's medical condition, response to treatment, and doctor's recommendation. It is crucial to follow the prescribed schedule to achieve optimal therapeutic effects. Patients should not attempt to self-administer this injection, and any concerns regarding dosage or side effects should be discussed with their doctor. Adequate hydration and regular monitoring may be required to manage potential side effects effectively.

Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them.

Serious

• Severe drop in blood cell count
• Heart problem
• Kidney damage
• Nerve damage
• Lung toxicity
• Liver toxicity

Common

• Cytomegalovirus infection
• Hemorrhage
• Diarrhea
• Blood in urine
• Rashes

It is advised to avoid ingestion, inhalation, or skin and eye contact of Tepapro 100mg Injection. Skin reactions may occur with accidental exposure. Using gloves and protective clothing to prevent accidental skin contact is recommended. If the Tepapro 100mg Injection solution contacts the skin or mucosa, immediately wash the skin thoroughly with soap and water or rinse the mucosa with water and seek medical attention.

1. ADIENNE SA, [Revised on 15th June 2020] [Accessed on 23 Nov 2022] https://pdf.hres.ca/dpd_pm/00056680.PDF
2. Pfizer, US Food and Drug Administration, [Revised on Jan 2017] [Accessed on 23 Nov 2022] https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208264s000lbl.pdf
3. Edward Chu, Cancer Chemotherapy, Lange’s Basic and Clinical Pharmacology, 14th Edition, 2018, 948-976.
4. KD Tripathi, Anticancer Drugs, Essentials of Medical Pharmacology, 8th Edition, 2019, 915-936.